Back to search

Article

Oral Pamapimod-Pioglitazone Combination (KIN001 ) vs Placebo in Hospitalized Non-Critically Ill COVID-19 Patients: The KINETIC (KIN001) to Reduce the Risk of EndoTracheal Intubation in COVID) Phase 2, Randomised, Double Blind, Placebo-Controlled Trial

2023-06-22

Abstract excerpt

Background: The combination of pamapimod, a p38 Mitogen activated protein kinase (p38 MAPK) inhibitor, with pioglitazone, a Peroxisome proliferator-activated receptor (PPAR) gamma agonist is designated KIN001. It has potent in vitro antiviral activity against SARS-CoV-2, and as p38 MAPK and PPAR-gamma are involved in inflammation and fibrosis, KIN001 may reduce the risk of development of severe COVID-19. The safet...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ac31945a-8bbd-53a1-baf1-5701f7a03491
DOI
10.2139/ssrn.4485627
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Oral Pamapimod-Pioglitazone Combination (KIN001 ) vs Placebo in Hospitalized Non-Critically Ill COVID-19 Patients: The KINETIC (KIN001) to Reduce the Risk of EndoTracheal Intubation in COVID) Phase 2, Randomised, Double Blind, Placebo-Controlled TrialDOI 10.2139/ssrn.4485627
A Randomized Open-Label Trial To Evaluate The Efficacy And Safety Of Triple Therapy With Aspirin, Atorvastatin, And Nicorandil In Hospitalised Patients With SARS Cov-2 Infection: A Structured Summary Of A Study Protocol For A Randomized Controlled TrialSemantic proximity
Adjunctive Use of Oral MAF is Associated with No Disease Progression or Mortality in Hospitalized Patients with COVID-19 Pneumonia: COral-MAF1 TrialSemantic proximity
Efficacy of Kan Jang® in Patients with Mild COVID-19: a Randomized, Quadruple-Blind, Placebo-Controlled TrialSemantic proximity
Capmatinib suppresses LPS-induced interaction between HUVECs and THP-1 monocytes through suppression of inflammatory responsesSemantic proximity
Target engagement analysis and link to pharmacodynamic endpoint for a novel class of CNS-penetrant and efficacious p38α MAPK inhibitors.Semantic proximity
Inhaled Aviptadil for the treatment of COVID-19 in patients at high risk for ARDS: Study protocol for a randomized, placebo controlled multicentre trial.Semantic proximity
A phase 2 study of the inhaled pan-JAK inhibitor TD-0903 in severe COVID-19: Part 1Semantic proximity
Early suPAR-Guided Anakinra Treatment in COVID-19 Pneumonia: Subgroup Analyses and 90-Day Outcomes of the SAVE-MORE TrialSemantic proximity
Select a neighboring publication to make it the new centre.